Nanovehicles for co-delivery of anticancer agents

Mahdi Zeinali, Soheil Abbaspour-Ravasjani, Marjan Ghorbani, Afshin Babazadeh, Tannaz Soltanfam, Ana Claudia Santos, Hamed Hamishehkar, Michael R. Hamblin*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Effective cancer treatment remains a significant challenge in human healthcare. Although many different types of cancer therapy have been tested, scientists have now concluded that combinations of drugs, or drugs plus gene therapy, can target multiple pathways to fight cancer. Nanovehicles can increase drug uptake inside tumor cells, improve biodistribution and accumulation at tumor sites. The ability to deliver two or more anticancer drugs, genes, among others, at the same time and place will increase therapeutic effects while decreasing side effects and reducing the risk of multidrug resistance. This review discusses the advantages of nano-based co-delivery methods in cancer therapy, summarizes the common types of nanovehicles and their preparation methods, and covers some recent co-delivery studies in detail.
Original languageEnglish
Pages (from-to)1416-1430
Number of pages15
JournalDrug Discovery Today
Volume25
Issue number8
DOIs
Publication statusPublished - Aug 2020

Fingerprint Dive into the research topics of 'Nanovehicles for co-delivery of anticancer agents'. Together they form a unique fingerprint.

  • Cite this

    Zeinali, M., Abbaspour-Ravasjani, S., Ghorbani, M., Babazadeh, A., Soltanfam, T., Claudia Santos, A., ... R. Hamblin, M. (2020). Nanovehicles for co-delivery of anticancer agents. Drug Discovery Today, 25(8), 1416-1430. https://doi.org/10.1016/j.drudis.2020.06.027